ATOS · Atossa Therapeutics, Inc. · Share Buybacks
$2.45
+0.11 (+4.70%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.”View the 10-Q filed Aug 7, 2026
Market Cap
$20.06M
Shares
9.98M
Volume · Oct 5
53.32K
Avg daily vol (3M)
74.18K
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$10,000,000
as of 2023-06-27
· not restated in filings since 2025-03-25
Equity Offering (ATM) Programs
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2024-12-31 | $0 | 10-K, filed 2025-03-25 |
| 2023-12-31 | $1,475,000 | 10-K, filed 2025-03-25 |
| 2022-12-31 | $0 | 10-K, filed 2024-04-01 |